RenalGuard Solutions Debuts Reprieve Cardiovascular, Inc.

September 12, 2018—Reprieve Cardiovascular, Inc. announced its formation as an affiliate of RenalGuard Solutions, Inc. Reprieve Cardiovascular and RenalGuard Solutions are subsidiaries of parent company CardioRenal Systems, Inc. RenalGuard also announced the completion of a $7 million financing round supported by existing investors, with Abiomed, Inc. as a participant and strategic lead.

Reprieve Cardiovascular's Guided Diuretic Therapy is being investigated as a treatment for patients who are fluid-overloaded because of heart failure. The treatment has the potential to speed decongestion while protecting core organ function, shorten hospital stays, and reduce rehospitalization in acute decompensated heart failure (ADHF) patients.

Reprieve Cardiovascular utilizes the RenalGuard platform, marketed by RenalGuard Solutions. The Reprieve technology is available for investigational use only in the United States.

The company will feature the Guided Diurectic Therapy at the Heart Failure Society of America’s 22nd Annual Scientific Meeting in Nashville, Tennessee on September 15–18, 2018. Initial results from a study demonstrating the feasibility of using Reprieve Cardiovascular’s Guided Diuretic Therapy to optimize fluid management in ADHF patients while alleviating related symptoms were presented at Heart Failure 2018 in May.

Maria R. Costanzo, MD, commented in the announcement, “I have been impressed with the early experience in the EU, led by Prof. Ponikowski in Wroclaw, Poland, for treating patients with acutely decompensated heart failure with the Reprieve Cardiovascular technology. Effective decongestion is critical to the ability to eventually reduce hospital length of stay and readmissions. The proposed mechanism of action of Reprieve Cardiovascular’s Guided Diuretic Therapy is based on important physiological principles and can potentially address the problem of fluid overload in many heart failure patients. I am eager to offer this therapy to my patients once the appropriate clinical trials have confirmed its safety and effectiveness.” Dr. Costanza is a cardiologist at Advocate Good Samaritan Hospital in Downers Grove, Illinois.